International Clinical Trials in Dermatology/Plastic Surgery

Argentina

• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Buenos Aires ; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Córdoba; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  San Isidro; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Tucuman; Research Site:
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  La Plata; Instituto Medico Platense
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Provincia de Buenos Aires; Instituto Medico
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Provincia de Santa Fe, Santa Fe; ISIS Clinica Especializada
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Buenos Aires; Hospital Britanico de Buenos Aires
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Buenos Aires; Hospital Militar Central
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Buenos Aires; Hospital Municipal de Oncologia Maria Curie
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Buenos Aires; Hospital General de Agudos Carlos G. Durand
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Cordoba; Hospital Privado de Cordoba S.A.
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Buenos Aires; Instituto Médico Especializado Alexander Fleming
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Cordoba; Instituto Oncologico De Cordoba
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Santa Fe; Isis Clinica Especializada
  
  

Australia

• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Parkville; Research Site:
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Waratah, NSW; Newcastle Melanoma Unit
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Nedlands; Sir Charles Gairdner Hospital
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Wodonga, Vic; Murray Valley Private Hospital and Cancer Treatment Center
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  South Brisbane, Qld; Mater Adult Hospital
  
  
• Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
  Adelaide, South Australia; Medical Oncology
  
  
• Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
  Fremantle; Fremantle Hospital
  
  
• Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
  Hobart, Tasmania; Royal Hobart Hospital
  
  
• Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
  Lismore, NS; Lismore Base Hospital, Cancer Care & Haematology Unit
  
  
• Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
  Redcliffe; Redcliffe Hospital
  
  
• Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
  Waratah; Newcastle Melanoma Unit
  
  
• Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
  Wollongong; Clinical Trials
  
  
• Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
  Wooloongabba; Princess Alexandra Hospital
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Box Hill; Department Of Medical Oncology, Box Hill Hospital
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Coffs Harbour; Coffs Harbour Health Campus
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Newcastle; David Maddison Building
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Port Macquarie; Port Macquarie Base Hospital
  
  

Austria

• Malignant Melanoma: A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
  Wien; Research Site:
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Innsbruck; Universitaet Innsbruck
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Wien; Akh Wien
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Wien; Wilhelminenspital Der Stadt Wien
  
  

Belgium

• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Bruxelles; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Liege; Research Site:
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Bruselles; Institut Jules Bordet
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Brasschaat; Az Klina
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Bruxelles; Cliniques Universitaires Saint-Luc
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Charleroi; Centre Hospitalier Notre Dame Et Reine Fabiola
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Edegem; University Hospital Antwerp
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Gent; Universitair Ziekenhuis Gent
  
  

Brazil

• Atopic Dermatitis: A Study of Protopic (Tacrolimus) Ointment in Children With Atopic Dermatitis
  Belo Horizonte; Research Site:
  
  
• Atopic Dermatitis: A Study of Protopic (Tacrolimus) Ointment in Children With Atopic Dermatitis
  Guarulhos; Research Site:
  
  
• Atopic Dermatitis: A Study of Protopic (Tacrolimus) Ointment in Children With Atopic Dermatitis
  Porto Alegre; Research Site:
  
  
• Atopic Dermatitis: A Study of Protopic (Tacrolimus) Ointment in Children With Atopic Dermatitis
  Sao Paulo; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Rio De Janeiro; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Sao Paulo; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Sorocaba; Research Site:
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Sao Paulo, SP; Hospital das Clinicas-Faculdade de Medicina da Universidade de Sao Paulo
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Sao Paulo, SP; Sociedade Baneficente de Senhoras - Hospital
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Porto Alegre, RS; Fundacao Central Sul-Americana para o Desenvolvimento de Novas Drogas
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Goiana, GO; Associacao de Combate ao Cancer de Goias
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Londrina, PR; Pro-Onco Centro De Tratamento Oncologico S/C Ltda
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Santo Andre, SP; Santo Andre Diagnosticos e Tratamentos Ltda
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Barretos, Sao Paulo; Hospital De Cancer De Barretos
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Jau, Sao Paulo; Fundacao Hospital Amaral Carvalho
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Porto Alegre, Rio Grande Do Sul; Santa Casa De Porto Alegre
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Porto Alegre, Rio Grande Do Sul; Hospital De Clínicas De Porto Alegre
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Porto Alegre, Rio Grande Do Sul; Hospital Sao Lucas - Pucrs
  
  
• Psoriasis and Psoriatic Disorders: A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis.
  Belem; Research Site:
  
  
• Psoriasis and Psoriatic Disorders: A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis.
  Belo Horizonte; Research Site:
  
  
• Psoriasis and Psoriatic Disorders: A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis.
  Botucatu; Research Site:
  
  
• Psoriasis and Psoriatic Disorders: A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis.
  Brasilia; Research Site:
  
  
• Psoriasis and Psoriatic Disorders: A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis.
  Campinas; Research Site:
  
  
• Psoriasis and Psoriatic Disorders: A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis.
  Curitiba; Research Site:
  
  
• Psoriasis and Psoriatic Disorders: A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis.
  Rio De Janeiro; Research Site:
  
  
• Psoriasis and Psoriatic Disorders: A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis.
  Salvador; Research Site:
  
  
• Psoriasis and Psoriatic Disorders: A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis.
  Sao Paulo; Research Site:
  
  

Canada

• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Montreal, QC; Research Site:
  
  
• Malignant Melanoma: A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
  Calgary, AB; Research Site:
  
  
• Malignant Melanoma: A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
  Edmonton, AB; Research Site:
  
  
• Malignant Melanoma: A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
  Montreal, QC; Research Site:
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Edmonton, Alberta; Cross Cancer Institute
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Winnipeg, Manitoba; St. Boniface Hospital
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Winnipeg, Manitoba; St. Boniface Hospital
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  St. John's, Newfoundland; The Dr. H. Bliss Murphy
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Edmonton, AL; Cross Cancer Institute
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  London, Ontario; London Regional Cancer Program
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Calgary , Alberta; Tom Baker Cancer Center
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Calgary, Ab; Tom Baker Cancer Centre
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Edmonton, Ab; Cross Cancer Institute
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Montreal, Qc; Hopital Du Sacre-Coeur De Montreal
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Quebec, Qc; Hotel Dieu De Quebec
  
  
• Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
  Calgary, Alberta; Tom Baker Cancer Centre
  
  
• Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
  Edmonton, Alberta; Cross Cancer Institute
  
  
• Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
  Halifax, Nova Scotia; QE II Health Sciences Center
  
  
• Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
  Montreal, Quebec; Royal Victoria Hospital
  
  
• Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
  Sudbury, Ontario; Northeastern Ontario Regional Cancer Centre
  
  
• Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
  Weston, Ontario; Humber River Regional Hospital
  
  
• Pemphigus Vulgaris (PV): A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
  Montreal, QC; Research Site:
  
  
• Pemphigus Vulgaris (PV): A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
  Toronto, ON; Research Site:
  
  
• Psoriasis and Psoriatic Disorders: A topical treatment for body psoriasis in adolescents
  St. John's, Newfoundland; Newlab Clinical Research, Inc.
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Montreal; Smbd Jewish General Hospital
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Montreal; Hopital Maisonneuve-Rosemont
  
  

Chile

• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Renaca; Clinica Renaca
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Santigo; Clinica Davila
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Santiago; Clinica Davila
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Santiago; Fundacion Arturo Lopez Perez
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Santiago; Instituto Nacional del Cancer
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Santiago; Fundacion Arturo Lopez Perez
  
  

China

• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Beijing; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Guangdong; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Guangzhou; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Jiangsu; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Shanghai; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis.
  Beijing; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis.
  Guangzhou; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis.
  Hangzhou; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis.
  Nanjing; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis.
  Shanghai; Research Site:
  
  

Czech Republic

• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Praha; Research Site:
  
  

Denmark

• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Aarhus C; Aarhus University Hospital
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Odense C; Odense University Hospital
  
  

France

• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Lille; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Lyon; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Paris; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Toulouse; Research Site:
  
  
• Malignant Melanoma: A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
  Bordeaux; Research Site:
  
  
• Malignant Melanoma: A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
  Marseille; Research Site:
  
  
• Malignant Melanoma: A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
  Nantes; Research Site:
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Vandoeuvre les Nancy; Centre Alexis Vautrin
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Lyon Cedex 8; Depertment de Cancerlolgie
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Lille Cedex; Service d'oncologie medicale
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Rennes cedex; Service d'oncologie Medicale
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Lyon Cedex 08; Centre Leon Berard
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Paris; Hopital Saint- Louis
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Paris Cedex 13; Groupe Hospitalier Pitie-Salpetriere
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Vandoeuvre Les Nancy; Centre Alexis Vautrin
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Villejuif; Institut Gustave Roussy
  
  
• Mycosis Fungoides: If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
  Lyoin; Hôpital de L’Hôtel Dieu
  
  
• Mycosis Fungoides: If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
  Nice; Hôpital Archet II
  
  
• Mycosis Fungoides: If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
  Paris Cedex 10; Hôpital Saint-Louis
  
  
• Mycosis Fungoides: If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
  Pierre Bénite; Centre Hospitalier Lyon Sud
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Bordeaux; Hopital Saint Andre
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Brest; Hopital Morvan
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Lyon; Hopital Hotel Dieu
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Marseille Cedex 09; Hopital Sainte Marguerite
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Nantes; Hotel Dieu
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Paris Cedex 10; Hopital Saint Louis
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Saint Etienne; Chu De Saint Etienne
  
  

Germany

• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Aachen; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Berlin; Research Site:
  
  
• Malignant Melanoma: A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
  Kiel; Research Site:
  
  
• Malignant Melanoma: A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
  Mannheim; Research Site:
  
  
• Malignant Melanoma: A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
  Tübingen; Research Site:
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Augsburg; Klinik f. Dermatologie
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Mannheim; Universitatsklinikum Mannheim
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Heidelberg; Universitatsklinikum Heidelberg
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Regensburg; Klinikum der Universitat Regensburg
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Wurzburg; Universitatsklinikum Wurzburg
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Essen; Universitatsklinikum Essen
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Berlin; Charite-Universitaets
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Berlin; Charite-Universitaets
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Jena; Klinikum der Friedrich - Schiller- Universitat Jena
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Erlangen; Poliklinik fur Kinder und Jugendliche
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Kiel; Universitatsklinukum Schleswig-Holstein
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Tubingen; Universitatsklinikum Tubingen
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Frankfurt; Klinikum D. Johann Wolfgang Goethe-Universitaet
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Graz; Lkh Universitaetsklinikum Graz
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Homburg / Saar; Universitaetsklinikum Des Saarlandes
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Jena; Klinikum Der Friedrich-Schiller-Universitat Jena
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Kiel; Universitaetsklinikum Schleswig-Holstein
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Mainz; Klinikum Der Johannes Gutenberg Universitaet Mainz
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Mannheim; Universitaetsklinikum Mannheim
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Tubingen; Universitatsklinikum Tuebingen
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Wuerzburg; Universitaetsklinikum Wuerzburg
  
  
• Mycosis Fungoides: If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
  Essen; University of Essen, Dept. of Dermatology
  
  
• Mycosis Fungoides: If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
  Kiel; University of Kiel
  
  
• Mycosis Fungoides: If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
  Minden; Akademisches Lehrkrankenhaus der medizinischen Hochschule Hannover
  
  
• Mycosis Fungoides: If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
  Würzburg; University of Würzburg
  
  
• Pemphigus Vulgaris (PV): A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
  Frankfurt Am Main; Research Site:
  
  
• Pemphigus Vulgaris (PV): A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
  Heidelberg; Research Site:
  
  
• Pemphigus Vulgaris (PV): A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
  Köln; Research Site:
  
  
• Pemphigus Vulgaris (PV): A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
  Mainz; Research Site:
  
  
• Pemphigus Vulgaris (PV): A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
  Münster; Research Site:
  
  
• Pemphigus Vulgaris (PV): A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
  Ulm; Research Site:
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Wurzburg; Universitatsklinikum Wurzburg
  
  

Greece

• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Athens; Research Site:
  
  

Hungary

• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Debrecen; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Szeged; Research Site:
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Gyula; Pandy Kalman Megyei Korhaz
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Miskolc; Semmelweis Korhaz Rendelointezet
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Szegedi; Szgedi Tudomanyegyetern
  
  

Israel

• Pemphigus Vulgaris (PV): A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
  Haifa; Research Site:
  
  
• Pemphigus Vulgaris (PV): A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
  Petah Tikva; Research Site:
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Haifa; Rambam Medical Center
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Holon; Wolfson Medical Center
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Jerusalem; Hadassah Hebrew University Hospital
  
  

Italy

• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Padova; Research Site:
  
  
• Malignant Melanoma: A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
  Siena; Local Institution
  
  
• Malignant Melanoma: A Study of Avastin (Bevacizumab) in Combination With Dacarbazine in Patients With Unresectable/Metastatic Melanoma.
  Milano; Research Site:
  
  
• Malignant Melanoma: A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma.
  Firenze; Research Site:
  
  
• Malignant Melanoma: A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma.
  Genova; Research Site:
  
  
• Malignant Melanoma: A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma.
  Milano; Research Site:
  
  
• Malignant Melanoma: A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma.
  Napoli; Research Site:
  
  
• Malignant Melanoma: A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma.
  Torino; Research Site:
  
  
• Malignant Melanoma: A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
  Milano; Research Site:
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Genove; Istituto Nazionale Per La Ricerca Sul Cancro
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Milano; Istituto Europeo Di Oncologia
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Napoli; Istituto Nazionale Per Lo Studio E La Cura Dei Tumori
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Padova; Istituto Oncologico Veneto
  
  
• Melanoma: A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom
  Siena; Policlinico Santa Maria Alle Scotte
  
  
• Mycosis Fungoides: If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
  Bologna; Instituto di Ematologia e Oncologia Medica L. & A. Seragnoli
  
  
• Mycosis Fungoides: If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
  Florence; University of Florence Medical School Department of Dermatology
  
  
• Mycosis Fungoides: If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
  Rome; IDI-IRCCS
  
  
• Mycosis Fungoides: If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
  Turin; University of Turin
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Genova; Istituto Nazionale Per La Ricerca Sul Cancro - Oncologia Med
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Milano; Istituto Europeo Di Oncologia
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Napoli; Istituto Nazionale Tumori Fondazione Pascale
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Padova; Istituto Oncologico Veneto
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Siena; Azienda Ospedaleira Universitaria Senese S. Maria Alle Scott
  
  

Mexico

• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Mexico City; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  San Luis Potosi; Research Site:
  
  

Netherlands

• Malignant Melanoma: A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
  Rotterdam; Research Site:
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Eindhoven; Catharina Ziekenhuis
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Mb Amsterdam; Vu Medical Centre
  
  

Norway

• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Oslo; Department Of Clinical Cancer Research
  
  

Poland

• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Gdansk; Wojewodzkie Centrum Onkologii
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Lodz; Regionalny Osrodek Onkolologiczy Wojewodzkii Szpital Specjal
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Lublin; Centrum Onkologii Ziemi Lubelskiej
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Poznan; Wielkopolskie Centrum Onkologii
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Wroclaw; Wojewodzki Szpital Specjalistyczny
  
  

Portugal

• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Coimbra; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Lisboa; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Porto; Research Site:
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Coimbra; Ipo De Coimbra Fg E.P.E.
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Lisboa; Instituto Portugues De Oncologia De Lisboa Fg E.P.E.
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Porto; Ipo Do Porto Fg E.P.E.
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Setubal; Hospital De Sao Bernardo
  
  

Romania

• Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
  Brasov; Oncology Department County Hospital Brasov
  
  
• Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
  Cluj Napoca; Oncology Institute Prof. Dr. Ion Chiricuta
  
  
• Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
  Cluj Napoca; Oncology Institute Prof. Dr. Ion Chiricuta
  
  
• Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
  Hunedoara; Clinical County Hospital Alexandru Simionescu Hunedoara
  
  
• Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
  Iasi; Center of Medical Oncology
  
  
• Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
  Sibiu; Clinical County Hospital Sibiu
  
  
• Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
  Timisoara; Oncology- Chemotherapy Clinic
  
  

Russian Federation

• Malignant Melanoma: A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
  Rayazan; Local Institution
  
  
• Malignant Melanoma: A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
  Voronezh; Local Institution
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Barnaul; Altai Regional Oncology Dispensary
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Moscow; N. N. Blokhin Russian Cancer Research Center
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Murmansk; Murmansk Regional Oncology Dispensary
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Ryazan; Regional Clinical Oncology Dispensary
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Samara; Samara Regional Oncology Dispensary
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  St Petersburg; City Clinical Oncology Dispensary
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  St. Petersburg; Leningrad Regional Oncology Center
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Stavropol; Stavropol Regional Clinical Oncology Center
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Voronezh; Voronezh Regional Clinical Oncology Center
  
  

S. Africa

• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Panorama; GVI Oncology
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Port Elizabeth; Eastern Cape Oncology Centre
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Groenkloof, Praetoria; Mary Potter Oncology Centre
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Sandton; Sandton Oncology
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Johannesburg, Gauteng; The Medical Oncology Centre of Rosebank
  
  

South Africa

• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Pretoria; Wilgers Oncology Centre
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Johannesburg; Sandton Oncology Centre
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Panorama; Gvi Oncology Centre
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Port Elizabeth; Eastern Cape Oncology Centre
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Pretoria; Wilgers Oncology Center
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Saxonwold; Medical Oncology Center Of Rosebank
  
  

Spain

• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Barcelona; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Malaga; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Sevilla; Research Site:
  
  
• Malignant Melanoma: A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
  Madrid; Research Site:
  
  
• Malignant Melanoma: A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
  Valencia; Research Site:
  
  
• Mycosis Fungoides: If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
  Madrid; Maternidad Planta Baja
  
  
• Mycosis Fungoides: If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
  Madrid; Hospital Universitario de la Princesa
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Canarias; Hospital Univ. De Canarias
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Malaga; Hospital Universitario Virgen De La Victoria
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Valencia; Hospital General Universitario
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Zaragoza; Hospital Universitario Miguel Servet
  
  

Switzerland

• Malignant Melanoma: A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
  Zürich; Research Site:
  
  
• Pemphigus Vulgaris (PV): A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
  Zürich; Research Site:
  
  

The Netherlands

• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Amsterdam; Vrije Universiteit Medisch Centrum (VUMC)
  
  

Turkey

• Pemphigus Vulgaris (PV): A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
  Ankara; Research Site:
  
  
• Pemphigus Vulgaris (PV): A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
  Istanbul; Research Site:
  
  

Ukraine

• Pemphigus Vulgaris (PV): A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
  Crimea; Research Site:
  
  
• Pemphigus Vulgaris (PV): A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
  Donetsk; Research Site:
  
  
• Pemphigus Vulgaris (PV): A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
  Kiev; Research Site:
  
  
• Pemphigus Vulgaris (PV): A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
  Lugnansk; Research Site:
  
  
• Pemphigus Vulgaris (PV): A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
  Uzhgorod; Research Site:
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Cherkassy; Cherkassy Regional Oncology Dispensary
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Dnepropetrovsk; Dnepropetrovsk State Medical Academy
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Kiev; Institute Of Oncology Ams Of Ukraine
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Lviv; Lviv State Oncology Regional Treatment And Diagnostic Centre
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Uzhgorod; Uzhgorod National University
  
  

United Kingdom

• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Cambridge; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Leeds; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  London; Research Site:
  
  
• Malignant Melanoma: A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
  Glasgow; Research Site:
  
  
• Malignant Melanoma: A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma
  Northwood; Research Site:
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Leeds; St. James University Hospital
  
  
• Pemphigus Vulgaris (PV): A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
  Leicester; Research Site:
  
  
• Pemphigus Vulgaris (PV): A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
  London; Research Site:
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  London; The Royal Marsden Hospital
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Wirral; Clatterbridge Centre For Oncology
  
  

USA

• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Barretos, SP; Hospital de Cancer de Barretos - Fundacao
  
  

Venezuela

• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis.
  Barquisimeto; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis.
  Caracas; Research Site: